Why did Eli Lilly's shares jump 4% premarket on Monday?

Eli Lilly's shares jumped 4% premarket on Monday due to compelling new clinical trial data for its next-generation obesity drug, retatrutide, presented at the American Diabetes Association meeting in New Orleans — specifically, the 4 mg dose demonstrated ~19% weight loss in obesity patients, comparable to the highest dose of Zepbound (tirzepatide), with tolerability broadly in line and relatively low vomiting rates.

How does retatrutide’s 4 mg dose compare to current standard-of-care obesity treatments in terms of efficacy and tolerability?

The 4 mg dose of retatrutide produced roughly 19% weight loss — comparable to the highest dose of Zepbound — while maintaining tolerability broadly in line with existing therapies, including similar treatment discontinuation rates and relatively low levels of vomiting; however, side effects increased at higher doses, reinforcing the 4 mg dose as a key candidate for first-line positioning per Citi analysts.

Lilly Shares Jump as Analysts See Retatrutide Data Extending Obesity Market Edge

Jun 8, 2026

Eli Lilly shares rose 4% following compelling Phase III data for obesity drug retatrutide, showing 19% weight loss at a lower dose. Analysts view this as strengthening Lilly's leadership against rivals in the $200 billion incretin market.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026